Skip to content

Pulmonary Rehabilitation in Patients With Fibrotic Interstitial Lung Disease

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00415272
Enrollment
Unknown
Registered
2006-12-22
Start date
Unknown
Completion date
2007-07-31
Last updated
2008-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibrotic Interstitial Lung Disease

Brief summary

Our study aims to investigate the benefits of an outpatient pulmonary rehabilitation program in a population of subjects with fibrotic interstitial lung disease. Our hypothesis is that pulmonary rehabilitation will lead to improvements in quality of life, breathlessness, exercise capacity and pulmonary function in this patient population.

Interventions

BEHAVIORALPulmonary Rehabilitation

Sponsors

University of California, San Francisco
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL

Inclusion criteria

1. Restriction on pulmonary function testing (TLC \<80%, FEV1/FVC ratio \> predicted or DLCO \< 80%) 2. Evidence of fibrosis on high resolution computed tomography of the chest. 3. Fibrosis on surgical lung biopsy if performed 4. Referral for pulmonary rehabilitation

Exclusion criteria

1. Participation in pulmonary rehabilitation in the past 24 months 2. Inability to complete 6 minute walk test or study questionnaires 3. Limitations other than dyspnea (e.g. arthritis) that affect ability to participate in pulmonary rehabilitation 4. Baseline 6 minute walk distance \> 400 meters 5. Planned change in medication treatment for lung disease during the course of pulmonary rehabilitation 6. Ejection fraction known to be \< 25% 7. Contraindications to pulmonary rehabilitation (clinically unstable, uncontrolled arrhythmia or hypertension, symptomatic or uncontrolled hypotension with systolic blood pressure of \< 95, active angina, unexplained syncope or worsening dizziness, limiting orthopedic or neurological disorders, psychiatric impairment that inhibits cooperation in the program) 8. FEV1/FVC \< 65% 9. Unable to provide informed consent

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026